BACKGROUND: Lung cancer screening with annual chest computed tomography (CT) is recommended for current and former smokers with a ≥30-pack-year smoking history. Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of developing lung cancer and may benefit from screening at lower pack-year thresholds. METHODS: We used a previously validated simulation model to compare the health benefits of lung cancer screening in current and former smokers ages 55-80 with ≥30 pack-years with hypothetical programs using lower pack-year thresholds for individuals with COPD (≥20, ≥10, and ≥1 pack-years). Calibration targets for COPD prevalence and associated lung cancer risk were derived using the Framingham Offspring Study limited data set. We performed sensitivity analyses to evaluate the stability of results across different rates of adherence to screening, increased competing mortality risk from COPD, and increased surgical ineligibility in individuals with COPD. The primary outcome was projected life expectancy. RESULTS: Programs using lower pack-year thresholds for individuals with COPD yielded the highest life expectancy gains for a given number of screens. Highest life expectancy was achieved when lowering the pack-year threshold to ≥1 pack-year for individuals with COPD, which dominated all other screening strategies. These results were stable across different adherence rates to screening and increases in competing mortality risk for COPD and surgical ineligibility. CONCLUSIONS: Current and former smokers with COPD may disproportionately benefit from lung cancer screening. A lower pack-year threshold for screening eligibility may benefit this high-risk patient population.
BACKGROUND:Lung cancer screening with annual chest computed tomography (CT) is recommended for current and former smokers with a ≥30-pack-year smoking history. Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of developing lung cancer and may benefit from screening at lower pack-year thresholds. METHODS: We used a previously validated simulation model to compare the health benefits of lung cancer screening in current and former smokers ages 55-80 with ≥30 pack-years with hypothetical programs using lower pack-year thresholds for individuals with COPD (≥20, ≥10, and ≥1 pack-years). Calibration targets for COPD prevalence and associated lung cancer risk were derived using the Framingham Offspring Study limited data set. We performed sensitivity analyses to evaluate the stability of results across different rates of adherence to screening, increased competing mortality risk from COPD, and increased surgical ineligibility in individuals with COPD. The primary outcome was projected life expectancy. RESULTS: Programs using lower pack-year thresholds for individuals with COPD yielded the highest life expectancy gains for a given number of screens. Highest life expectancy was achieved when lowering the pack-year threshold to ≥1 pack-year for individuals with COPD, which dominated all other screening strategies. These results were stable across different adherence rates to screening and increases in competing mortality risk for COPD and surgical ineligibility. CONCLUSIONS: Current and former smokers with COPD may disproportionately benefit from lung cancer screening. A lower pack-year threshold for screening eligibility may benefit this high-risk patient population.
Authors: R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger Journal: Eur Respir J Date: 2005-11 Impact factor: 16.671
Authors: R J Givelber; N N Couropmitree; D J Gottlieb; J C Evans; D Levy; R H Myers; G T O'Connor Journal: Am J Respir Crit Care Med Date: 1998-05 Impact factor: 21.405
Authors: A Papi; G Casoni; G Caramori; I Guzzinati; P Boschetto; F Ravenna; N Calia; S Petruzzelli; L Corbetta; G Cavallesco; E Forini; M Saetta; A Ciaccia; L M Fabbri Journal: Thorax Date: 2004-08 Impact factor: 9.139
Authors: Raewyn J Hopkins; Fenghai Duan; Caroline Chiles; Erin M Greco; Greg D Gamble; Denise Aberle; Robert P Young Journal: Ann Am Thorac Soc Date: 2017-03
Authors: Barbara Bp Yawn; Byron Thomashaw; David M Mannino; MeiLan K Han; Ravi Kalhan; Stephen Rennard; Scott Cerrata; James D Crapo; Robert Wise Journal: Chronic Obstr Pulm Dis Date: 2017-07-15
Authors: Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2018-04 Impact factor: 11.908
Authors: Aleksandra Undrunas; Piotr Kasprzyk; Aleksandra Rajca; Krzysztof Kuziemski; Witold Rzyman; Tomasz Zdrojewski Journal: BMJ Open Date: 2022-04-11 Impact factor: 2.692
Authors: Sylvie Leroy; Jonathan Benzaquen; Andrea Mazzetta; Sylvain Marchand-Adam; Bernard Padovani; Dominique Israel-Biet; Christophe Pison; Pascal Chanez; Jacques Cadranel; Julien Mazières; Vincent Jounieaux; Charlotte Cohen; Véronique Hofman; Marius Ilie; Paul Hofman; Charles Hugo Marquette Journal: BMJ Open Date: 2017-12-26 Impact factor: 2.692
Authors: Bangi A Naseer; Abdullah M Al-Shenqiti; AbdulRahman H Ali; Talal M Al-Jeraisi; Garg G Gunjan; Mohammed F Awaidallah Journal: J Taibah Univ Med Sci Date: 2017-08-23